A federal appeals court just refused to pump the brakes on marijuana rescheduling

On September 9, a three-judge panel of the U.S. Court of Appeals for the D.C. Circuit — Robert Wilkins, Justin Walker and Bradley Garcia — denied a request to stay the Justice Department's April order moving state-licensed medical marijuana and FDA-approved marijuana drug products from Schedule I to Schedule III. The challengers, a drug-testing trade association and cannabinoid-drug companies including MedPharma Iowa and Tri-Mountain Pure, argued DOJ skipped procedural steps normally required to reclassify a controlled substance.

The panel found the challengers hadn't cleared the "stringent requirements" for a stay pending review — meaning Schedule III stays in effect for the operators and products it currently covers while the underlying case moves forward. Nothing about the ruling settles the actual merits: the D.C. Circuit still has to decide whether DOJ's process was lawful, and the parties have 30 days to propose how briefing on that question should proceed.

It's a procedural win, not a final one, but timing matters. Every month the reclassification survives intact is another month operators keep the reduced tax exposure and easier banking access that came with leaving Schedule I — relief that would evaporate instantly if the court eventually sides with the challengers and marijuana reverts to Schedule I.

For MSOs and state-licensed operators who built Q3 and Q4 financial plans around Schedule III's tax relief, the practical read is: keep planning around it, but don't treat it as locked in. The case isn't over, and a trade group with real standing to challenge the order isn't going away just because it lost round one.